Global Ganirelix Market

Ganirelix Comprehensive Study by Application (Infertility, Controlled Ovarian Stimulation, IVF Treatment, Premature Ovarian Failure (POF)), Form (Injection, Solution), Packaging (Single syringe, Box of 5, Box of 50), Clearance (Single Dose: 2.4L/hour, Multiple Dose: 3.3L/hour), Strength (0.25 mg/0.5ml, 250 µg/0.5ml, 0.5 mg/1ml), Route (Subcutaneous, Parenteral) Players and Region - Global Market Outlook to 2030

Ganirelix Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 3.9%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Ganirelix
Ganirelix acetate (or diacetate), which is sold under the brand names Orgalutran and Antagon, is an injectable competitive gonadotropin-releasing hormone antagonist (GnRH antagonist). It is mainly used in assisted reproduction to control ovulation. Ganirelix is used as a drug used to treat fertility in people with ovaries. In particular, it is used to prevent premature ovulation in people with ovaries who are undergoing fertility treatment that involves overstimulation of the ovaries, causing the ovaries to produce multiple eggs. When such premature ovulation occurs, the eggs released by the ovaries may be too immature to be used for in vitro fertilization. Ganirelix hereby prevents ovulation until the period it is triggered by injecting the human chorionic gonadotropin (hCG). Ganirelix is given by the subcutaneous injection of 250 µg once daily during the mid to late follicular phase of a patient's menstrual cycle. Treatment should begin on the 5th or 6th day after the start of ovarian stimulation. The average duration of use is five days.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR3.9%


The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Organon USA Inc. (United States), Ferring Pharmaceuticals Inc. (United States), Sun Pharmaceutical Industries Ltd. (India), Chemenu Inc. (China), Merck & Co., Inc. (United States), BLD Pharm (China), LGM Pharma (United States) and Angle Bio Pharma (India) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Ganirelix market by , Application (Infertility, Controlled Ovarian Stimulation, IVF Treatment and Premature Ovarian Failure (POF)) and Region.



On the basis of geography, the market of Ganirelix has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Form, the sub-segment i.e. Injection will boost the Ganirelix market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Packaging, the sub-segment i.e. Single syringe will boost the Ganirelix market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Clearance, the sub-segment i.e. Single Dose: 2.4L/hour will boost the Ganirelix market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Strength, the sub-segment i.e. 0.25 mg/0.5ml will boost the Ganirelix market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route, the sub-segment i.e. Subcutaneous will boost the Ganirelix market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Advancements in Infertility Treatment

Market Growth Drivers:
Declining Fertility Rate and Rising Number of Fertility Clinics Worldwide

Challenges:
Lack of Medical Infrastructure in Underdeveloped Countries and Reduced Efficacy among Older Women

Restraints:
Stringent Government Regulations and The High Cost of Ganirelix

Opportunities:
Improving Healthcare Infrastructure in Developing Countries and Increasing Medical Tourism

Market Leaders and their expansionary development strategies
In February 2023, Ferring Pharmaceuticals and Revive Therapeutics announced a collaboration to develop and commercialize Revive's RLH-030, a long-acting GnRH antagonist containing ganirelix, for the treatment of endometriosis and uterine fibroids.
In September 2023No new Ganirelix-based products were launched in 2023. However, Ferring Pharmaceuticals did announce the expansion of the Ganirelix product line with the launch of a pre-filled syringe in select European markets.


Key Target Audience
Providers of Ganirelix, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Infertility
  • Controlled Ovarian Stimulation
  • IVF Treatment
  • Premature Ovarian Failure (POF)
By Form
  • Injection
  • Solution

By Packaging
  • Single syringe
  • Box of 5
  • Box of 50

By Clearance
  • Single Dose: 2.4L/hour
  • Multiple Dose: 3.3L/hour

By Strength
  • 0.25 mg/0.5ml
  • 250 µg/0.5ml
  • 0.5 mg/1ml

By Route
  • Subcutaneous
  • Parenteral

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Declining Fertility Rate
      • 3.2.2. Rising Number of Fertility Clinics Worldwide
    • 3.3. Market Challenges
      • 3.3.1. Lack of Medical Infrastructure in Underdeveloped Countries
      • 3.3.2. Reduced Efficacy among Older Women
    • 3.4. Market Trends
      • 3.4.1. Advancements in Infertility Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Ganirelix, by Application, Form, Packaging, Clearance, Strength, Route and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Ganirelix (Value)
      • 5.2.1. Global Ganirelix by: Application (Value)
        • 5.2.1.1. Infertility
        • 5.2.1.2. Controlled Ovarian Stimulation
        • 5.2.1.3. IVF Treatment
        • 5.2.1.4. Premature Ovarian Failure (POF)
      • 5.2.2. Global Ganirelix by: Form (Value)
        • 5.2.2.1. Injection
        • 5.2.2.2. Solution
      • 5.2.3. Global Ganirelix by: Packaging (Value)
        • 5.2.3.1. Single syringe
        • 5.2.3.2. Box of 5
        • 5.2.3.3. Box of 50
      • 5.2.4. Global Ganirelix by: Clearance (Value)
        • 5.2.4.1. Single Dose: 2.4L/hour
        • 5.2.4.2. Multiple Dose: 3.3L/hour
      • 5.2.5. Global Ganirelix by: Strength (Value)
        • 5.2.5.1. 0.25 mg/0.5ml
        • 5.2.5.2. 250 µg/0.5ml
        • 5.2.5.3. 0.5 mg/1ml
      • 5.2.6. Global Ganirelix by: Route (Value)
        • 5.2.6.1. Subcutaneous
        • 5.2.6.2. Parenteral
      • 5.2.7. Global Ganirelix Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
    • 5.3. Global Ganirelix (Volume)
      • 5.3.1. Global Ganirelix by: Application (Volume)
        • 5.3.1.1. Infertility
        • 5.3.1.2. Controlled Ovarian Stimulation
        • 5.3.1.3. IVF Treatment
        • 5.3.1.4. Premature Ovarian Failure (POF)
      • 5.3.2. Global Ganirelix by: Form (Volume)
        • 5.3.2.1. Injection
        • 5.3.2.2. Solution
      • 5.3.3. Global Ganirelix by: Packaging (Volume)
        • 5.3.3.1. Single syringe
        • 5.3.3.2. Box of 5
        • 5.3.3.3. Box of 50
      • 5.3.4. Global Ganirelix by: Clearance (Volume)
        • 5.3.4.1. Single Dose: 2.4L/hour
        • 5.3.4.2. Multiple Dose: 3.3L/hour
      • 5.3.5. Global Ganirelix by: Strength (Volume)
        • 5.3.5.1. 0.25 mg/0.5ml
        • 5.3.5.2. 250 µg/0.5ml
        • 5.3.5.3. 0.5 mg/1ml
      • 5.3.6. Global Ganirelix by: Route (Volume)
        • 5.3.6.1. Subcutaneous
        • 5.3.6.2. Parenteral
      • 5.3.7. Global Ganirelix Region
        • 5.3.7.1. South America
          • 5.3.7.1.1. Brazil
          • 5.3.7.1.2. Argentina
          • 5.3.7.1.3. Rest of South America
        • 5.3.7.2. Asia Pacific
          • 5.3.7.2.1. China
          • 5.3.7.2.2. Japan
          • 5.3.7.2.3. India
          • 5.3.7.2.4. South Korea
          • 5.3.7.2.5. Taiwan
          • 5.3.7.2.6. Australia
          • 5.3.7.2.7. Rest of Asia-Pacific
        • 5.3.7.3. Europe
          • 5.3.7.3.1. Germany
          • 5.3.7.3.2. France
          • 5.3.7.3.3. Italy
          • 5.3.7.3.4. United Kingdom
          • 5.3.7.3.5. Netherlands
          • 5.3.7.3.6. Rest of Europe
        • 5.3.7.4. MEA
          • 5.3.7.4.1. Middle East
          • 5.3.7.4.2. Africa
        • 5.3.7.5. North America
          • 5.3.7.5.1. United States
          • 5.3.7.5.2. Canada
          • 5.3.7.5.3. Mexico
    • 5.4. Global Ganirelix (Price)
  • 6. Ganirelix: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Organon USA Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Ferring Pharmaceuticals Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Chemenu Inc. (China)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co., Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. BLD Pharm (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. LGM Pharma (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Angle Bio Pharma (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Ganirelix Sale, by Application, Form, Packaging, Clearance, Strength, Route and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Ganirelix (Value)
      • 7.2.1. Global Ganirelix by: Application (Value)
        • 7.2.1.1. Infertility
        • 7.2.1.2. Controlled Ovarian Stimulation
        • 7.2.1.3. IVF Treatment
        • 7.2.1.4. Premature Ovarian Failure (POF)
      • 7.2.2. Global Ganirelix by: Form (Value)
        • 7.2.2.1. Injection
        • 7.2.2.2. Solution
      • 7.2.3. Global Ganirelix by: Packaging (Value)
        • 7.2.3.1. Single syringe
        • 7.2.3.2. Box of 5
        • 7.2.3.3. Box of 50
      • 7.2.4. Global Ganirelix by: Clearance (Value)
        • 7.2.4.1. Single Dose: 2.4L/hour
        • 7.2.4.2. Multiple Dose: 3.3L/hour
      • 7.2.5. Global Ganirelix by: Strength (Value)
        • 7.2.5.1. 0.25 mg/0.5ml
        • 7.2.5.2. 250 µg/0.5ml
        • 7.2.5.3. 0.5 mg/1ml
      • 7.2.6. Global Ganirelix by: Route (Value)
        • 7.2.6.1. Subcutaneous
        • 7.2.6.2. Parenteral
      • 7.2.7. Global Ganirelix Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
    • 7.3. Global Ganirelix (Volume)
      • 7.3.1. Global Ganirelix by: Application (Volume)
        • 7.3.1.1. Infertility
        • 7.3.1.2. Controlled Ovarian Stimulation
        • 7.3.1.3. IVF Treatment
        • 7.3.1.4. Premature Ovarian Failure (POF)
      • 7.3.2. Global Ganirelix by: Form (Volume)
        • 7.3.2.1. Injection
        • 7.3.2.2. Solution
      • 7.3.3. Global Ganirelix by: Packaging (Volume)
        • 7.3.3.1. Single syringe
        • 7.3.3.2. Box of 5
        • 7.3.3.3. Box of 50
      • 7.3.4. Global Ganirelix by: Clearance (Volume)
        • 7.3.4.1. Single Dose: 2.4L/hour
        • 7.3.4.2. Multiple Dose: 3.3L/hour
      • 7.3.5. Global Ganirelix by: Strength (Volume)
        • 7.3.5.1. 0.25 mg/0.5ml
        • 7.3.5.2. 250 µg/0.5ml
        • 7.3.5.3. 0.5 mg/1ml
      • 7.3.6. Global Ganirelix by: Route (Volume)
        • 7.3.6.1. Subcutaneous
        • 7.3.6.2. Parenteral
      • 7.3.7. Global Ganirelix Region
        • 7.3.7.1. South America
          • 7.3.7.1.1. Brazil
          • 7.3.7.1.2. Argentina
          • 7.3.7.1.3. Rest of South America
        • 7.3.7.2. Asia Pacific
          • 7.3.7.2.1. China
          • 7.3.7.2.2. Japan
          • 7.3.7.2.3. India
          • 7.3.7.2.4. South Korea
          • 7.3.7.2.5. Taiwan
          • 7.3.7.2.6. Australia
          • 7.3.7.2.7. Rest of Asia-Pacific
        • 7.3.7.3. Europe
          • 7.3.7.3.1. Germany
          • 7.3.7.3.2. France
          • 7.3.7.3.3. Italy
          • 7.3.7.3.4. United Kingdom
          • 7.3.7.3.5. Netherlands
          • 7.3.7.3.6. Rest of Europe
        • 7.3.7.4. MEA
          • 7.3.7.4.1. Middle East
          • 7.3.7.4.2. Africa
        • 7.3.7.5. North America
          • 7.3.7.5.1. United States
          • 7.3.7.5.2. Canada
          • 7.3.7.5.3. Mexico
    • 7.4. Global Ganirelix (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Ganirelix: by Application(USD Million)
  • Table 2. Ganirelix Infertility , by Region USD Million (2018-2023)
  • Table 3. Ganirelix Controlled Ovarian Stimulation , by Region USD Million (2018-2023)
  • Table 4. Ganirelix IVF Treatment , by Region USD Million (2018-2023)
  • Table 5. Ganirelix Premature Ovarian Failure (POF) , by Region USD Million (2018-2023)
  • Table 6. Ganirelix: by Form(USD Million)
  • Table 7. Ganirelix Injection , by Region USD Million (2018-2023)
  • Table 8. Ganirelix Solution , by Region USD Million (2018-2023)
  • Table 9. Ganirelix: by Packaging(USD Million)
  • Table 10. Ganirelix Single syringe , by Region USD Million (2018-2023)
  • Table 11. Ganirelix Box of 5 , by Region USD Million (2018-2023)
  • Table 12. Ganirelix Box of 50 , by Region USD Million (2018-2023)
  • Table 13. Ganirelix: by Clearance(USD Million)
  • Table 14. Ganirelix Single Dose: 2.4L/hour , by Region USD Million (2018-2023)
  • Table 15. Ganirelix Multiple Dose: 3.3L/hour , by Region USD Million (2018-2023)
  • Table 16. Ganirelix: by Strength(USD Million)
  • Table 17. Ganirelix 0.25 mg/0.5ml , by Region USD Million (2018-2023)
  • Table 18. Ganirelix 250 µg/0.5ml , by Region USD Million (2018-2023)
  • Table 19. Ganirelix 0.5 mg/1ml , by Region USD Million (2018-2023)
  • Table 20. Ganirelix: by Route(USD Million)
  • Table 21. Ganirelix Subcutaneous , by Region USD Million (2018-2023)
  • Table 22. Ganirelix Parenteral , by Region USD Million (2018-2023)
  • Table 23. South America Ganirelix, by Country USD Million (2018-2023)
  • Table 24. South America Ganirelix, by Application USD Million (2018-2023)
  • Table 25. South America Ganirelix, by Form USD Million (2018-2023)
  • Table 26. South America Ganirelix, by Packaging USD Million (2018-2023)
  • Table 27. South America Ganirelix, by Clearance USD Million (2018-2023)
  • Table 28. South America Ganirelix, by Strength USD Million (2018-2023)
  • Table 29. South America Ganirelix, by Route USD Million (2018-2023)
  • Table 30. Brazil Ganirelix, by Application USD Million (2018-2023)
  • Table 31. Brazil Ganirelix, by Form USD Million (2018-2023)
  • Table 32. Brazil Ganirelix, by Packaging USD Million (2018-2023)
  • Table 33. Brazil Ganirelix, by Clearance USD Million (2018-2023)
  • Table 34. Brazil Ganirelix, by Strength USD Million (2018-2023)
  • Table 35. Brazil Ganirelix, by Route USD Million (2018-2023)
  • Table 36. Argentina Ganirelix, by Application USD Million (2018-2023)
  • Table 37. Argentina Ganirelix, by Form USD Million (2018-2023)
  • Table 38. Argentina Ganirelix, by Packaging USD Million (2018-2023)
  • Table 39. Argentina Ganirelix, by Clearance USD Million (2018-2023)
  • Table 40. Argentina Ganirelix, by Strength USD Million (2018-2023)
  • Table 41. Argentina Ganirelix, by Route USD Million (2018-2023)
  • Table 42. Rest of South America Ganirelix, by Application USD Million (2018-2023)
  • Table 43. Rest of South America Ganirelix, by Form USD Million (2018-2023)
  • Table 44. Rest of South America Ganirelix, by Packaging USD Million (2018-2023)
  • Table 45. Rest of South America Ganirelix, by Clearance USD Million (2018-2023)
  • Table 46. Rest of South America Ganirelix, by Strength USD Million (2018-2023)
  • Table 47. Rest of South America Ganirelix, by Route USD Million (2018-2023)
  • Table 48. Asia Pacific Ganirelix, by Country USD Million (2018-2023)
  • Table 49. Asia Pacific Ganirelix, by Application USD Million (2018-2023)
  • Table 50. Asia Pacific Ganirelix, by Form USD Million (2018-2023)
  • Table 51. Asia Pacific Ganirelix, by Packaging USD Million (2018-2023)
  • Table 52. Asia Pacific Ganirelix, by Clearance USD Million (2018-2023)
  • Table 53. Asia Pacific Ganirelix, by Strength USD Million (2018-2023)
  • Table 54. Asia Pacific Ganirelix, by Route USD Million (2018-2023)
  • Table 55. China Ganirelix, by Application USD Million (2018-2023)
  • Table 56. China Ganirelix, by Form USD Million (2018-2023)
  • Table 57. China Ganirelix, by Packaging USD Million (2018-2023)
  • Table 58. China Ganirelix, by Clearance USD Million (2018-2023)
  • Table 59. China Ganirelix, by Strength USD Million (2018-2023)
  • Table 60. China Ganirelix, by Route USD Million (2018-2023)
  • Table 61. Japan Ganirelix, by Application USD Million (2018-2023)
  • Table 62. Japan Ganirelix, by Form USD Million (2018-2023)
  • Table 63. Japan Ganirelix, by Packaging USD Million (2018-2023)
  • Table 64. Japan Ganirelix, by Clearance USD Million (2018-2023)
  • Table 65. Japan Ganirelix, by Strength USD Million (2018-2023)
  • Table 66. Japan Ganirelix, by Route USD Million (2018-2023)
  • Table 67. India Ganirelix, by Application USD Million (2018-2023)
  • Table 68. India Ganirelix, by Form USD Million (2018-2023)
  • Table 69. India Ganirelix, by Packaging USD Million (2018-2023)
  • Table 70. India Ganirelix, by Clearance USD Million (2018-2023)
  • Table 71. India Ganirelix, by Strength USD Million (2018-2023)
  • Table 72. India Ganirelix, by Route USD Million (2018-2023)
  • Table 73. South Korea Ganirelix, by Application USD Million (2018-2023)
  • Table 74. South Korea Ganirelix, by Form USD Million (2018-2023)
  • Table 75. South Korea Ganirelix, by Packaging USD Million (2018-2023)
  • Table 76. South Korea Ganirelix, by Clearance USD Million (2018-2023)
  • Table 77. South Korea Ganirelix, by Strength USD Million (2018-2023)
  • Table 78. South Korea Ganirelix, by Route USD Million (2018-2023)
  • Table 79. Taiwan Ganirelix, by Application USD Million (2018-2023)
  • Table 80. Taiwan Ganirelix, by Form USD Million (2018-2023)
  • Table 81. Taiwan Ganirelix, by Packaging USD Million (2018-2023)
  • Table 82. Taiwan Ganirelix, by Clearance USD Million (2018-2023)
  • Table 83. Taiwan Ganirelix, by Strength USD Million (2018-2023)
  • Table 84. Taiwan Ganirelix, by Route USD Million (2018-2023)
  • Table 85. Australia Ganirelix, by Application USD Million (2018-2023)
  • Table 86. Australia Ganirelix, by Form USD Million (2018-2023)
  • Table 87. Australia Ganirelix, by Packaging USD Million (2018-2023)
  • Table 88. Australia Ganirelix, by Clearance USD Million (2018-2023)
  • Table 89. Australia Ganirelix, by Strength USD Million (2018-2023)
  • Table 90. Australia Ganirelix, by Route USD Million (2018-2023)
  • Table 91. Rest of Asia-Pacific Ganirelix, by Application USD Million (2018-2023)
  • Table 92. Rest of Asia-Pacific Ganirelix, by Form USD Million (2018-2023)
  • Table 93. Rest of Asia-Pacific Ganirelix, by Packaging USD Million (2018-2023)
  • Table 94. Rest of Asia-Pacific Ganirelix, by Clearance USD Million (2018-2023)
  • Table 95. Rest of Asia-Pacific Ganirelix, by Strength USD Million (2018-2023)
  • Table 96. Rest of Asia-Pacific Ganirelix, by Route USD Million (2018-2023)
  • Table 97. Europe Ganirelix, by Country USD Million (2018-2023)
  • Table 98. Europe Ganirelix, by Application USD Million (2018-2023)
  • Table 99. Europe Ganirelix, by Form USD Million (2018-2023)
  • Table 100. Europe Ganirelix, by Packaging USD Million (2018-2023)
  • Table 101. Europe Ganirelix, by Clearance USD Million (2018-2023)
  • Table 102. Europe Ganirelix, by Strength USD Million (2018-2023)
  • Table 103. Europe Ganirelix, by Route USD Million (2018-2023)
  • Table 104. Germany Ganirelix, by Application USD Million (2018-2023)
  • Table 105. Germany Ganirelix, by Form USD Million (2018-2023)
  • Table 106. Germany Ganirelix, by Packaging USD Million (2018-2023)
  • Table 107. Germany Ganirelix, by Clearance USD Million (2018-2023)
  • Table 108. Germany Ganirelix, by Strength USD Million (2018-2023)
  • Table 109. Germany Ganirelix, by Route USD Million (2018-2023)
  • Table 110. France Ganirelix, by Application USD Million (2018-2023)
  • Table 111. France Ganirelix, by Form USD Million (2018-2023)
  • Table 112. France Ganirelix, by Packaging USD Million (2018-2023)
  • Table 113. France Ganirelix, by Clearance USD Million (2018-2023)
  • Table 114. France Ganirelix, by Strength USD Million (2018-2023)
  • Table 115. France Ganirelix, by Route USD Million (2018-2023)
  • Table 116. Italy Ganirelix, by Application USD Million (2018-2023)
  • Table 117. Italy Ganirelix, by Form USD Million (2018-2023)
  • Table 118. Italy Ganirelix, by Packaging USD Million (2018-2023)
  • Table 119. Italy Ganirelix, by Clearance USD Million (2018-2023)
  • Table 120. Italy Ganirelix, by Strength USD Million (2018-2023)
  • Table 121. Italy Ganirelix, by Route USD Million (2018-2023)
  • Table 122. United Kingdom Ganirelix, by Application USD Million (2018-2023)
  • Table 123. United Kingdom Ganirelix, by Form USD Million (2018-2023)
  • Table 124. United Kingdom Ganirelix, by Packaging USD Million (2018-2023)
  • Table 125. United Kingdom Ganirelix, by Clearance USD Million (2018-2023)
  • Table 126. United Kingdom Ganirelix, by Strength USD Million (2018-2023)
  • Table 127. United Kingdom Ganirelix, by Route USD Million (2018-2023)
  • Table 128. Netherlands Ganirelix, by Application USD Million (2018-2023)
  • Table 129. Netherlands Ganirelix, by Form USD Million (2018-2023)
  • Table 130. Netherlands Ganirelix, by Packaging USD Million (2018-2023)
  • Table 131. Netherlands Ganirelix, by Clearance USD Million (2018-2023)
  • Table 132. Netherlands Ganirelix, by Strength USD Million (2018-2023)
  • Table 133. Netherlands Ganirelix, by Route USD Million (2018-2023)
  • Table 134. Rest of Europe Ganirelix, by Application USD Million (2018-2023)
  • Table 135. Rest of Europe Ganirelix, by Form USD Million (2018-2023)
  • Table 136. Rest of Europe Ganirelix, by Packaging USD Million (2018-2023)
  • Table 137. Rest of Europe Ganirelix, by Clearance USD Million (2018-2023)
  • Table 138. Rest of Europe Ganirelix, by Strength USD Million (2018-2023)
  • Table 139. Rest of Europe Ganirelix, by Route USD Million (2018-2023)
  • Table 140. MEA Ganirelix, by Country USD Million (2018-2023)
  • Table 141. MEA Ganirelix, by Application USD Million (2018-2023)
  • Table 142. MEA Ganirelix, by Form USD Million (2018-2023)
  • Table 143. MEA Ganirelix, by Packaging USD Million (2018-2023)
  • Table 144. MEA Ganirelix, by Clearance USD Million (2018-2023)
  • Table 145. MEA Ganirelix, by Strength USD Million (2018-2023)
  • Table 146. MEA Ganirelix, by Route USD Million (2018-2023)
  • Table 147. Middle East Ganirelix, by Application USD Million (2018-2023)
  • Table 148. Middle East Ganirelix, by Form USD Million (2018-2023)
  • Table 149. Middle East Ganirelix, by Packaging USD Million (2018-2023)
  • Table 150. Middle East Ganirelix, by Clearance USD Million (2018-2023)
  • Table 151. Middle East Ganirelix, by Strength USD Million (2018-2023)
  • Table 152. Middle East Ganirelix, by Route USD Million (2018-2023)
  • Table 153. Africa Ganirelix, by Application USD Million (2018-2023)
  • Table 154. Africa Ganirelix, by Form USD Million (2018-2023)
  • Table 155. Africa Ganirelix, by Packaging USD Million (2018-2023)
  • Table 156. Africa Ganirelix, by Clearance USD Million (2018-2023)
  • Table 157. Africa Ganirelix, by Strength USD Million (2018-2023)
  • Table 158. Africa Ganirelix, by Route USD Million (2018-2023)
  • Table 159. North America Ganirelix, by Country USD Million (2018-2023)
  • Table 160. North America Ganirelix, by Application USD Million (2018-2023)
  • Table 161. North America Ganirelix, by Form USD Million (2018-2023)
  • Table 162. North America Ganirelix, by Packaging USD Million (2018-2023)
  • Table 163. North America Ganirelix, by Clearance USD Million (2018-2023)
  • Table 164. North America Ganirelix, by Strength USD Million (2018-2023)
  • Table 165. North America Ganirelix, by Route USD Million (2018-2023)
  • Table 166. United States Ganirelix, by Application USD Million (2018-2023)
  • Table 167. United States Ganirelix, by Form USD Million (2018-2023)
  • Table 168. United States Ganirelix, by Packaging USD Million (2018-2023)
  • Table 169. United States Ganirelix, by Clearance USD Million (2018-2023)
  • Table 170. United States Ganirelix, by Strength USD Million (2018-2023)
  • Table 171. United States Ganirelix, by Route USD Million (2018-2023)
  • Table 172. Canada Ganirelix, by Application USD Million (2018-2023)
  • Table 173. Canada Ganirelix, by Form USD Million (2018-2023)
  • Table 174. Canada Ganirelix, by Packaging USD Million (2018-2023)
  • Table 175. Canada Ganirelix, by Clearance USD Million (2018-2023)
  • Table 176. Canada Ganirelix, by Strength USD Million (2018-2023)
  • Table 177. Canada Ganirelix, by Route USD Million (2018-2023)
  • Table 178. Mexico Ganirelix, by Application USD Million (2018-2023)
  • Table 179. Mexico Ganirelix, by Form USD Million (2018-2023)
  • Table 180. Mexico Ganirelix, by Packaging USD Million (2018-2023)
  • Table 181. Mexico Ganirelix, by Clearance USD Million (2018-2023)
  • Table 182. Mexico Ganirelix, by Strength USD Million (2018-2023)
  • Table 183. Mexico Ganirelix, by Route USD Million (2018-2023)
  • Table 184. Ganirelix Sales: by Application(K Units)
  • Table 185. Ganirelix Sales Infertility , by Region K Units (2018-2023)
  • Table 186. Ganirelix Sales Controlled Ovarian Stimulation , by Region K Units (2018-2023)
  • Table 187. Ganirelix Sales IVF Treatment , by Region K Units (2018-2023)
  • Table 188. Ganirelix Sales Premature Ovarian Failure (POF) , by Region K Units (2018-2023)
  • Table 189. Ganirelix Sales: by Form(K Units)
  • Table 190. Ganirelix Sales Injection , by Region K Units (2018-2023)
  • Table 191. Ganirelix Sales Solution , by Region K Units (2018-2023)
  • Table 192. Ganirelix Sales: by Packaging(K Units)
  • Table 193. Ganirelix Sales Single syringe , by Region K Units (2018-2023)
  • Table 194. Ganirelix Sales Box of 5 , by Region K Units (2018-2023)
  • Table 195. Ganirelix Sales Box of 50 , by Region K Units (2018-2023)
  • Table 196. Ganirelix Sales: by Clearance(K Units)
  • Table 197. Ganirelix Sales Single Dose: 2.4L/hour , by Region K Units (2018-2023)
  • Table 198. Ganirelix Sales Multiple Dose: 3.3L/hour , by Region K Units (2018-2023)
  • Table 199. Ganirelix Sales: by Strength(K Units)
  • Table 200. Ganirelix Sales 0.25 mg/0.5ml , by Region K Units (2018-2023)
  • Table 201. Ganirelix Sales 250 µg/0.5ml , by Region K Units (2018-2023)
  • Table 202. Ganirelix Sales 0.5 mg/1ml , by Region K Units (2018-2023)
  • Table 203. Ganirelix Sales: by Route(K Units)
  • Table 204. Ganirelix Sales Subcutaneous , by Region K Units (2018-2023)
  • Table 205. Ganirelix Sales Parenteral , by Region K Units (2018-2023)
  • Table 206. South America Ganirelix Sales, by Country K Units (2018-2023)
  • Table 207. South America Ganirelix Sales, by Application K Units (2018-2023)
  • Table 208. South America Ganirelix Sales, by Form K Units (2018-2023)
  • Table 209. South America Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 210. South America Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 211. South America Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 212. South America Ganirelix Sales, by Route K Units (2018-2023)
  • Table 213. Brazil Ganirelix Sales, by Application K Units (2018-2023)
  • Table 214. Brazil Ganirelix Sales, by Form K Units (2018-2023)
  • Table 215. Brazil Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 216. Brazil Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 217. Brazil Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 218. Brazil Ganirelix Sales, by Route K Units (2018-2023)
  • Table 219. Argentina Ganirelix Sales, by Application K Units (2018-2023)
  • Table 220. Argentina Ganirelix Sales, by Form K Units (2018-2023)
  • Table 221. Argentina Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 222. Argentina Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 223. Argentina Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 224. Argentina Ganirelix Sales, by Route K Units (2018-2023)
  • Table 225. Rest of South America Ganirelix Sales, by Application K Units (2018-2023)
  • Table 226. Rest of South America Ganirelix Sales, by Form K Units (2018-2023)
  • Table 227. Rest of South America Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 228. Rest of South America Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 229. Rest of South America Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 230. Rest of South America Ganirelix Sales, by Route K Units (2018-2023)
  • Table 231. Asia Pacific Ganirelix Sales, by Country K Units (2018-2023)
  • Table 232. Asia Pacific Ganirelix Sales, by Application K Units (2018-2023)
  • Table 233. Asia Pacific Ganirelix Sales, by Form K Units (2018-2023)
  • Table 234. Asia Pacific Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 235. Asia Pacific Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 236. Asia Pacific Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 237. Asia Pacific Ganirelix Sales, by Route K Units (2018-2023)
  • Table 238. China Ganirelix Sales, by Application K Units (2018-2023)
  • Table 239. China Ganirelix Sales, by Form K Units (2018-2023)
  • Table 240. China Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 241. China Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 242. China Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 243. China Ganirelix Sales, by Route K Units (2018-2023)
  • Table 244. Japan Ganirelix Sales, by Application K Units (2018-2023)
  • Table 245. Japan Ganirelix Sales, by Form K Units (2018-2023)
  • Table 246. Japan Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 247. Japan Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 248. Japan Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 249. Japan Ganirelix Sales, by Route K Units (2018-2023)
  • Table 250. India Ganirelix Sales, by Application K Units (2018-2023)
  • Table 251. India Ganirelix Sales, by Form K Units (2018-2023)
  • Table 252. India Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 253. India Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 254. India Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 255. India Ganirelix Sales, by Route K Units (2018-2023)
  • Table 256. South Korea Ganirelix Sales, by Application K Units (2018-2023)
  • Table 257. South Korea Ganirelix Sales, by Form K Units (2018-2023)
  • Table 258. South Korea Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 259. South Korea Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 260. South Korea Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 261. South Korea Ganirelix Sales, by Route K Units (2018-2023)
  • Table 262. Taiwan Ganirelix Sales, by Application K Units (2018-2023)
  • Table 263. Taiwan Ganirelix Sales, by Form K Units (2018-2023)
  • Table 264. Taiwan Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 265. Taiwan Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 266. Taiwan Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 267. Taiwan Ganirelix Sales, by Route K Units (2018-2023)
  • Table 268. Australia Ganirelix Sales, by Application K Units (2018-2023)
  • Table 269. Australia Ganirelix Sales, by Form K Units (2018-2023)
  • Table 270. Australia Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 271. Australia Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 272. Australia Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 273. Australia Ganirelix Sales, by Route K Units (2018-2023)
  • Table 274. Rest of Asia-Pacific Ganirelix Sales, by Application K Units (2018-2023)
  • Table 275. Rest of Asia-Pacific Ganirelix Sales, by Form K Units (2018-2023)
  • Table 276. Rest of Asia-Pacific Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 277. Rest of Asia-Pacific Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 278. Rest of Asia-Pacific Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 279. Rest of Asia-Pacific Ganirelix Sales, by Route K Units (2018-2023)
  • Table 280. Europe Ganirelix Sales, by Country K Units (2018-2023)
  • Table 281. Europe Ganirelix Sales, by Application K Units (2018-2023)
  • Table 282. Europe Ganirelix Sales, by Form K Units (2018-2023)
  • Table 283. Europe Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 284. Europe Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 285. Europe Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 286. Europe Ganirelix Sales, by Route K Units (2018-2023)
  • Table 287. Germany Ganirelix Sales, by Application K Units (2018-2023)
  • Table 288. Germany Ganirelix Sales, by Form K Units (2018-2023)
  • Table 289. Germany Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 290. Germany Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 291. Germany Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 292. Germany Ganirelix Sales, by Route K Units (2018-2023)
  • Table 293. France Ganirelix Sales, by Application K Units (2018-2023)
  • Table 294. France Ganirelix Sales, by Form K Units (2018-2023)
  • Table 295. France Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 296. France Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 297. France Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 298. France Ganirelix Sales, by Route K Units (2018-2023)
  • Table 299. Italy Ganirelix Sales, by Application K Units (2018-2023)
  • Table 300. Italy Ganirelix Sales, by Form K Units (2018-2023)
  • Table 301. Italy Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 302. Italy Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 303. Italy Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 304. Italy Ganirelix Sales, by Route K Units (2018-2023)
  • Table 305. United Kingdom Ganirelix Sales, by Application K Units (2018-2023)
  • Table 306. United Kingdom Ganirelix Sales, by Form K Units (2018-2023)
  • Table 307. United Kingdom Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 308. United Kingdom Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 309. United Kingdom Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 310. United Kingdom Ganirelix Sales, by Route K Units (2018-2023)
  • Table 311. Netherlands Ganirelix Sales, by Application K Units (2018-2023)
  • Table 312. Netherlands Ganirelix Sales, by Form K Units (2018-2023)
  • Table 313. Netherlands Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 314. Netherlands Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 315. Netherlands Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 316. Netherlands Ganirelix Sales, by Route K Units (2018-2023)
  • Table 317. Rest of Europe Ganirelix Sales, by Application K Units (2018-2023)
  • Table 318. Rest of Europe Ganirelix Sales, by Form K Units (2018-2023)
  • Table 319. Rest of Europe Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 320. Rest of Europe Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 321. Rest of Europe Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 322. Rest of Europe Ganirelix Sales, by Route K Units (2018-2023)
  • Table 323. MEA Ganirelix Sales, by Country K Units (2018-2023)
  • Table 324. MEA Ganirelix Sales, by Application K Units (2018-2023)
  • Table 325. MEA Ganirelix Sales, by Form K Units (2018-2023)
  • Table 326. MEA Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 327. MEA Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 328. MEA Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 329. MEA Ganirelix Sales, by Route K Units (2018-2023)
  • Table 330. Middle East Ganirelix Sales, by Application K Units (2018-2023)
  • Table 331. Middle East Ganirelix Sales, by Form K Units (2018-2023)
  • Table 332. Middle East Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 333. Middle East Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 334. Middle East Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 335. Middle East Ganirelix Sales, by Route K Units (2018-2023)
  • Table 336. Africa Ganirelix Sales, by Application K Units (2018-2023)
  • Table 337. Africa Ganirelix Sales, by Form K Units (2018-2023)
  • Table 338. Africa Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 339. Africa Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 340. Africa Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 341. Africa Ganirelix Sales, by Route K Units (2018-2023)
  • Table 342. North America Ganirelix Sales, by Country K Units (2018-2023)
  • Table 343. North America Ganirelix Sales, by Application K Units (2018-2023)
  • Table 344. North America Ganirelix Sales, by Form K Units (2018-2023)
  • Table 345. North America Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 346. North America Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 347. North America Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 348. North America Ganirelix Sales, by Route K Units (2018-2023)
  • Table 349. United States Ganirelix Sales, by Application K Units (2018-2023)
  • Table 350. United States Ganirelix Sales, by Form K Units (2018-2023)
  • Table 351. United States Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 352. United States Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 353. United States Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 354. United States Ganirelix Sales, by Route K Units (2018-2023)
  • Table 355. Canada Ganirelix Sales, by Application K Units (2018-2023)
  • Table 356. Canada Ganirelix Sales, by Form K Units (2018-2023)
  • Table 357. Canada Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 358. Canada Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 359. Canada Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 360. Canada Ganirelix Sales, by Route K Units (2018-2023)
  • Table 361. Mexico Ganirelix Sales, by Application K Units (2018-2023)
  • Table 362. Mexico Ganirelix Sales, by Form K Units (2018-2023)
  • Table 363. Mexico Ganirelix Sales, by Packaging K Units (2018-2023)
  • Table 364. Mexico Ganirelix Sales, by Clearance K Units (2018-2023)
  • Table 365. Mexico Ganirelix Sales, by Strength K Units (2018-2023)
  • Table 366. Mexico Ganirelix Sales, by Route K Units (2018-2023)
  • Table 367. Company Basic Information, Sales Area and Its Competitors
  • Table 368. Company Basic Information, Sales Area and Its Competitors
  • Table 369. Company Basic Information, Sales Area and Its Competitors
  • Table 370. Company Basic Information, Sales Area and Its Competitors
  • Table 371. Company Basic Information, Sales Area and Its Competitors
  • Table 372. Company Basic Information, Sales Area and Its Competitors
  • Table 373. Company Basic Information, Sales Area and Its Competitors
  • Table 374. Company Basic Information, Sales Area and Its Competitors
  • Table 375. Ganirelix: by Application(USD Million)
  • Table 376. Ganirelix Infertility , by Region USD Million (2025-2030)
  • Table 377. Ganirelix Controlled Ovarian Stimulation , by Region USD Million (2025-2030)
  • Table 378. Ganirelix IVF Treatment , by Region USD Million (2025-2030)
  • Table 379. Ganirelix Premature Ovarian Failure (POF) , by Region USD Million (2025-2030)
  • Table 380. Ganirelix: by Form(USD Million)
  • Table 381. Ganirelix Injection , by Region USD Million (2025-2030)
  • Table 382. Ganirelix Solution , by Region USD Million (2025-2030)
  • Table 383. Ganirelix: by Packaging(USD Million)
  • Table 384. Ganirelix Single syringe , by Region USD Million (2025-2030)
  • Table 385. Ganirelix Box of 5 , by Region USD Million (2025-2030)
  • Table 386. Ganirelix Box of 50 , by Region USD Million (2025-2030)
  • Table 387. Ganirelix: by Clearance(USD Million)
  • Table 388. Ganirelix Single Dose: 2.4L/hour , by Region USD Million (2025-2030)
  • Table 389. Ganirelix Multiple Dose: 3.3L/hour , by Region USD Million (2025-2030)
  • Table 390. Ganirelix: by Strength(USD Million)
  • Table 391. Ganirelix 0.25 mg/0.5ml , by Region USD Million (2025-2030)
  • Table 392. Ganirelix 250 µg/0.5ml , by Region USD Million (2025-2030)
  • Table 393. Ganirelix 0.5 mg/1ml , by Region USD Million (2025-2030)
  • Table 394. Ganirelix: by Route(USD Million)
  • Table 395. Ganirelix Subcutaneous , by Region USD Million (2025-2030)
  • Table 396. Ganirelix Parenteral , by Region USD Million (2025-2030)
  • Table 397. South America Ganirelix, by Country USD Million (2025-2030)
  • Table 398. South America Ganirelix, by Application USD Million (2025-2030)
  • Table 399. South America Ganirelix, by Form USD Million (2025-2030)
  • Table 400. South America Ganirelix, by Packaging USD Million (2025-2030)
  • Table 401. South America Ganirelix, by Clearance USD Million (2025-2030)
  • Table 402. South America Ganirelix, by Strength USD Million (2025-2030)
  • Table 403. South America Ganirelix, by Route USD Million (2025-2030)
  • Table 404. Brazil Ganirelix, by Application USD Million (2025-2030)
  • Table 405. Brazil Ganirelix, by Form USD Million (2025-2030)
  • Table 406. Brazil Ganirelix, by Packaging USD Million (2025-2030)
  • Table 407. Brazil Ganirelix, by Clearance USD Million (2025-2030)
  • Table 408. Brazil Ganirelix, by Strength USD Million (2025-2030)
  • Table 409. Brazil Ganirelix, by Route USD Million (2025-2030)
  • Table 410. Argentina Ganirelix, by Application USD Million (2025-2030)
  • Table 411. Argentina Ganirelix, by Form USD Million (2025-2030)
  • Table 412. Argentina Ganirelix, by Packaging USD Million (2025-2030)
  • Table 413. Argentina Ganirelix, by Clearance USD Million (2025-2030)
  • Table 414. Argentina Ganirelix, by Strength USD Million (2025-2030)
  • Table 415. Argentina Ganirelix, by Route USD Million (2025-2030)
  • Table 416. Rest of South America Ganirelix, by Application USD Million (2025-2030)
  • Table 417. Rest of South America Ganirelix, by Form USD Million (2025-2030)
  • Table 418. Rest of South America Ganirelix, by Packaging USD Million (2025-2030)
  • Table 419. Rest of South America Ganirelix, by Clearance USD Million (2025-2030)
  • Table 420. Rest of South America Ganirelix, by Strength USD Million (2025-2030)
  • Table 421. Rest of South America Ganirelix, by Route USD Million (2025-2030)
  • Table 422. Asia Pacific Ganirelix, by Country USD Million (2025-2030)
  • Table 423. Asia Pacific Ganirelix, by Application USD Million (2025-2030)
  • Table 424. Asia Pacific Ganirelix, by Form USD Million (2025-2030)
  • Table 425. Asia Pacific Ganirelix, by Packaging USD Million (2025-2030)
  • Table 426. Asia Pacific Ganirelix, by Clearance USD Million (2025-2030)
  • Table 427. Asia Pacific Ganirelix, by Strength USD Million (2025-2030)
  • Table 428. Asia Pacific Ganirelix, by Route USD Million (2025-2030)
  • Table 429. China Ganirelix, by Application USD Million (2025-2030)
  • Table 430. China Ganirelix, by Form USD Million (2025-2030)
  • Table 431. China Ganirelix, by Packaging USD Million (2025-2030)
  • Table 432. China Ganirelix, by Clearance USD Million (2025-2030)
  • Table 433. China Ganirelix, by Strength USD Million (2025-2030)
  • Table 434. China Ganirelix, by Route USD Million (2025-2030)
  • Table 435. Japan Ganirelix, by Application USD Million (2025-2030)
  • Table 436. Japan Ganirelix, by Form USD Million (2025-2030)
  • Table 437. Japan Ganirelix, by Packaging USD Million (2025-2030)
  • Table 438. Japan Ganirelix, by Clearance USD Million (2025-2030)
  • Table 439. Japan Ganirelix, by Strength USD Million (2025-2030)
  • Table 440. Japan Ganirelix, by Route USD Million (2025-2030)
  • Table 441. India Ganirelix, by Application USD Million (2025-2030)
  • Table 442. India Ganirelix, by Form USD Million (2025-2030)
  • Table 443. India Ganirelix, by Packaging USD Million (2025-2030)
  • Table 444. India Ganirelix, by Clearance USD Million (2025-2030)
  • Table 445. India Ganirelix, by Strength USD Million (2025-2030)
  • Table 446. India Ganirelix, by Route USD Million (2025-2030)
  • Table 447. South Korea Ganirelix, by Application USD Million (2025-2030)
  • Table 448. South Korea Ganirelix, by Form USD Million (2025-2030)
  • Table 449. South Korea Ganirelix, by Packaging USD Million (2025-2030)
  • Table 450. South Korea Ganirelix, by Clearance USD Million (2025-2030)
  • Table 451. South Korea Ganirelix, by Strength USD Million (2025-2030)
  • Table 452. South Korea Ganirelix, by Route USD Million (2025-2030)
  • Table 453. Taiwan Ganirelix, by Application USD Million (2025-2030)
  • Table 454. Taiwan Ganirelix, by Form USD Million (2025-2030)
  • Table 455. Taiwan Ganirelix, by Packaging USD Million (2025-2030)
  • Table 456. Taiwan Ganirelix, by Clearance USD Million (2025-2030)
  • Table 457. Taiwan Ganirelix, by Strength USD Million (2025-2030)
  • Table 458. Taiwan Ganirelix, by Route USD Million (2025-2030)
  • Table 459. Australia Ganirelix, by Application USD Million (2025-2030)
  • Table 460. Australia Ganirelix, by Form USD Million (2025-2030)
  • Table 461. Australia Ganirelix, by Packaging USD Million (2025-2030)
  • Table 462. Australia Ganirelix, by Clearance USD Million (2025-2030)
  • Table 463. Australia Ganirelix, by Strength USD Million (2025-2030)
  • Table 464. Australia Ganirelix, by Route USD Million (2025-2030)
  • Table 465. Rest of Asia-Pacific Ganirelix, by Application USD Million (2025-2030)
  • Table 466. Rest of Asia-Pacific Ganirelix, by Form USD Million (2025-2030)
  • Table 467. Rest of Asia-Pacific Ganirelix, by Packaging USD Million (2025-2030)
  • Table 468. Rest of Asia-Pacific Ganirelix, by Clearance USD Million (2025-2030)
  • Table 469. Rest of Asia-Pacific Ganirelix, by Strength USD Million (2025-2030)
  • Table 470. Rest of Asia-Pacific Ganirelix, by Route USD Million (2025-2030)
  • Table 471. Europe Ganirelix, by Country USD Million (2025-2030)
  • Table 472. Europe Ganirelix, by Application USD Million (2025-2030)
  • Table 473. Europe Ganirelix, by Form USD Million (2025-2030)
  • Table 474. Europe Ganirelix, by Packaging USD Million (2025-2030)
  • Table 475. Europe Ganirelix, by Clearance USD Million (2025-2030)
  • Table 476. Europe Ganirelix, by Strength USD Million (2025-2030)
  • Table 477. Europe Ganirelix, by Route USD Million (2025-2030)
  • Table 478. Germany Ganirelix, by Application USD Million (2025-2030)
  • Table 479. Germany Ganirelix, by Form USD Million (2025-2030)
  • Table 480. Germany Ganirelix, by Packaging USD Million (2025-2030)
  • Table 481. Germany Ganirelix, by Clearance USD Million (2025-2030)
  • Table 482. Germany Ganirelix, by Strength USD Million (2025-2030)
  • Table 483. Germany Ganirelix, by Route USD Million (2025-2030)
  • Table 484. France Ganirelix, by Application USD Million (2025-2030)
  • Table 485. France Ganirelix, by Form USD Million (2025-2030)
  • Table 486. France Ganirelix, by Packaging USD Million (2025-2030)
  • Table 487. France Ganirelix, by Clearance USD Million (2025-2030)
  • Table 488. France Ganirelix, by Strength USD Million (2025-2030)
  • Table 489. France Ganirelix, by Route USD Million (2025-2030)
  • Table 490. Italy Ganirelix, by Application USD Million (2025-2030)
  • Table 491. Italy Ganirelix, by Form USD Million (2025-2030)
  • Table 492. Italy Ganirelix, by Packaging USD Million (2025-2030)
  • Table 493. Italy Ganirelix, by Clearance USD Million (2025-2030)
  • Table 494. Italy Ganirelix, by Strength USD Million (2025-2030)
  • Table 495. Italy Ganirelix, by Route USD Million (2025-2030)
  • Table 496. United Kingdom Ganirelix, by Application USD Million (2025-2030)
  • Table 497. United Kingdom Ganirelix, by Form USD Million (2025-2030)
  • Table 498. United Kingdom Ganirelix, by Packaging USD Million (2025-2030)
  • Table 499. United Kingdom Ganirelix, by Clearance USD Million (2025-2030)
  • Table 500. United Kingdom Ganirelix, by Strength USD Million (2025-2030)
  • Table 501. United Kingdom Ganirelix, by Route USD Million (2025-2030)
  • Table 502. Netherlands Ganirelix, by Application USD Million (2025-2030)
  • Table 503. Netherlands Ganirelix, by Form USD Million (2025-2030)
  • Table 504. Netherlands Ganirelix, by Packaging USD Million (2025-2030)
  • Table 505. Netherlands Ganirelix, by Clearance USD Million (2025-2030)
  • Table 506. Netherlands Ganirelix, by Strength USD Million (2025-2030)
  • Table 507. Netherlands Ganirelix, by Route USD Million (2025-2030)
  • Table 508. Rest of Europe Ganirelix, by Application USD Million (2025-2030)
  • Table 509. Rest of Europe Ganirelix, by Form USD Million (2025-2030)
  • Table 510. Rest of Europe Ganirelix, by Packaging USD Million (2025-2030)
  • Table 511. Rest of Europe Ganirelix, by Clearance USD Million (2025-2030)
  • Table 512. Rest of Europe Ganirelix, by Strength USD Million (2025-2030)
  • Table 513. Rest of Europe Ganirelix, by Route USD Million (2025-2030)
  • Table 514. MEA Ganirelix, by Country USD Million (2025-2030)
  • Table 515. MEA Ganirelix, by Application USD Million (2025-2030)
  • Table 516. MEA Ganirelix, by Form USD Million (2025-2030)
  • Table 517. MEA Ganirelix, by Packaging USD Million (2025-2030)
  • Table 518. MEA Ganirelix, by Clearance USD Million (2025-2030)
  • Table 519. MEA Ganirelix, by Strength USD Million (2025-2030)
  • Table 520. MEA Ganirelix, by Route USD Million (2025-2030)
  • Table 521. Middle East Ganirelix, by Application USD Million (2025-2030)
  • Table 522. Middle East Ganirelix, by Form USD Million (2025-2030)
  • Table 523. Middle East Ganirelix, by Packaging USD Million (2025-2030)
  • Table 524. Middle East Ganirelix, by Clearance USD Million (2025-2030)
  • Table 525. Middle East Ganirelix, by Strength USD Million (2025-2030)
  • Table 526. Middle East Ganirelix, by Route USD Million (2025-2030)
  • Table 527. Africa Ganirelix, by Application USD Million (2025-2030)
  • Table 528. Africa Ganirelix, by Form USD Million (2025-2030)
  • Table 529. Africa Ganirelix, by Packaging USD Million (2025-2030)
  • Table 530. Africa Ganirelix, by Clearance USD Million (2025-2030)
  • Table 531. Africa Ganirelix, by Strength USD Million (2025-2030)
  • Table 532. Africa Ganirelix, by Route USD Million (2025-2030)
  • Table 533. North America Ganirelix, by Country USD Million (2025-2030)
  • Table 534. North America Ganirelix, by Application USD Million (2025-2030)
  • Table 535. North America Ganirelix, by Form USD Million (2025-2030)
  • Table 536. North America Ganirelix, by Packaging USD Million (2025-2030)
  • Table 537. North America Ganirelix, by Clearance USD Million (2025-2030)
  • Table 538. North America Ganirelix, by Strength USD Million (2025-2030)
  • Table 539. North America Ganirelix, by Route USD Million (2025-2030)
  • Table 540. United States Ganirelix, by Application USD Million (2025-2030)
  • Table 541. United States Ganirelix, by Form USD Million (2025-2030)
  • Table 542. United States Ganirelix, by Packaging USD Million (2025-2030)
  • Table 543. United States Ganirelix, by Clearance USD Million (2025-2030)
  • Table 544. United States Ganirelix, by Strength USD Million (2025-2030)
  • Table 545. United States Ganirelix, by Route USD Million (2025-2030)
  • Table 546. Canada Ganirelix, by Application USD Million (2025-2030)
  • Table 547. Canada Ganirelix, by Form USD Million (2025-2030)
  • Table 548. Canada Ganirelix, by Packaging USD Million (2025-2030)
  • Table 549. Canada Ganirelix, by Clearance USD Million (2025-2030)
  • Table 550. Canada Ganirelix, by Strength USD Million (2025-2030)
  • Table 551. Canada Ganirelix, by Route USD Million (2025-2030)
  • Table 552. Mexico Ganirelix, by Application USD Million (2025-2030)
  • Table 553. Mexico Ganirelix, by Form USD Million (2025-2030)
  • Table 554. Mexico Ganirelix, by Packaging USD Million (2025-2030)
  • Table 555. Mexico Ganirelix, by Clearance USD Million (2025-2030)
  • Table 556. Mexico Ganirelix, by Strength USD Million (2025-2030)
  • Table 557. Mexico Ganirelix, by Route USD Million (2025-2030)
  • Table 558. Ganirelix Sales: by Application(K Units)
  • Table 559. Ganirelix Sales Infertility , by Region K Units (2025-2030)
  • Table 560. Ganirelix Sales Controlled Ovarian Stimulation , by Region K Units (2025-2030)
  • Table 561. Ganirelix Sales IVF Treatment , by Region K Units (2025-2030)
  • Table 562. Ganirelix Sales Premature Ovarian Failure (POF) , by Region K Units (2025-2030)
  • Table 563. Ganirelix Sales: by Form(K Units)
  • Table 564. Ganirelix Sales Injection , by Region K Units (2025-2030)
  • Table 565. Ganirelix Sales Solution , by Region K Units (2025-2030)
  • Table 566. Ganirelix Sales: by Packaging(K Units)
  • Table 567. Ganirelix Sales Single syringe , by Region K Units (2025-2030)
  • Table 568. Ganirelix Sales Box of 5 , by Region K Units (2025-2030)
  • Table 569. Ganirelix Sales Box of 50 , by Region K Units (2025-2030)
  • Table 570. Ganirelix Sales: by Clearance(K Units)
  • Table 571. Ganirelix Sales Single Dose: 2.4L/hour , by Region K Units (2025-2030)
  • Table 572. Ganirelix Sales Multiple Dose: 3.3L/hour , by Region K Units (2025-2030)
  • Table 573. Ganirelix Sales: by Strength(K Units)
  • Table 574. Ganirelix Sales 0.25 mg/0.5ml , by Region K Units (2025-2030)
  • Table 575. Ganirelix Sales 250 µg/0.5ml , by Region K Units (2025-2030)
  • Table 576. Ganirelix Sales 0.5 mg/1ml , by Region K Units (2025-2030)
  • Table 577. Ganirelix Sales: by Route(K Units)
  • Table 578. Ganirelix Sales Subcutaneous , by Region K Units (2025-2030)
  • Table 579. Ganirelix Sales Parenteral , by Region K Units (2025-2030)
  • Table 580. South America Ganirelix Sales, by Country K Units (2025-2030)
  • Table 581. South America Ganirelix Sales, by Application K Units (2025-2030)
  • Table 582. South America Ganirelix Sales, by Form K Units (2025-2030)
  • Table 583. South America Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 584. South America Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 585. South America Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 586. South America Ganirelix Sales, by Route K Units (2025-2030)
  • Table 587. Brazil Ganirelix Sales, by Application K Units (2025-2030)
  • Table 588. Brazil Ganirelix Sales, by Form K Units (2025-2030)
  • Table 589. Brazil Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 590. Brazil Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 591. Brazil Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 592. Brazil Ganirelix Sales, by Route K Units (2025-2030)
  • Table 593. Argentina Ganirelix Sales, by Application K Units (2025-2030)
  • Table 594. Argentina Ganirelix Sales, by Form K Units (2025-2030)
  • Table 595. Argentina Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 596. Argentina Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 597. Argentina Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 598. Argentina Ganirelix Sales, by Route K Units (2025-2030)
  • Table 599. Rest of South America Ganirelix Sales, by Application K Units (2025-2030)
  • Table 600. Rest of South America Ganirelix Sales, by Form K Units (2025-2030)
  • Table 601. Rest of South America Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 602. Rest of South America Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 603. Rest of South America Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 604. Rest of South America Ganirelix Sales, by Route K Units (2025-2030)
  • Table 605. Asia Pacific Ganirelix Sales, by Country K Units (2025-2030)
  • Table 606. Asia Pacific Ganirelix Sales, by Application K Units (2025-2030)
  • Table 607. Asia Pacific Ganirelix Sales, by Form K Units (2025-2030)
  • Table 608. Asia Pacific Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 609. Asia Pacific Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 610. Asia Pacific Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 611. Asia Pacific Ganirelix Sales, by Route K Units (2025-2030)
  • Table 612. China Ganirelix Sales, by Application K Units (2025-2030)
  • Table 613. China Ganirelix Sales, by Form K Units (2025-2030)
  • Table 614. China Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 615. China Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 616. China Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 617. China Ganirelix Sales, by Route K Units (2025-2030)
  • Table 618. Japan Ganirelix Sales, by Application K Units (2025-2030)
  • Table 619. Japan Ganirelix Sales, by Form K Units (2025-2030)
  • Table 620. Japan Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 621. Japan Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 622. Japan Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 623. Japan Ganirelix Sales, by Route K Units (2025-2030)
  • Table 624. India Ganirelix Sales, by Application K Units (2025-2030)
  • Table 625. India Ganirelix Sales, by Form K Units (2025-2030)
  • Table 626. India Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 627. India Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 628. India Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 629. India Ganirelix Sales, by Route K Units (2025-2030)
  • Table 630. South Korea Ganirelix Sales, by Application K Units (2025-2030)
  • Table 631. South Korea Ganirelix Sales, by Form K Units (2025-2030)
  • Table 632. South Korea Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 633. South Korea Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 634. South Korea Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 635. South Korea Ganirelix Sales, by Route K Units (2025-2030)
  • Table 636. Taiwan Ganirelix Sales, by Application K Units (2025-2030)
  • Table 637. Taiwan Ganirelix Sales, by Form K Units (2025-2030)
  • Table 638. Taiwan Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 639. Taiwan Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 640. Taiwan Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 641. Taiwan Ganirelix Sales, by Route K Units (2025-2030)
  • Table 642. Australia Ganirelix Sales, by Application K Units (2025-2030)
  • Table 643. Australia Ganirelix Sales, by Form K Units (2025-2030)
  • Table 644. Australia Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 645. Australia Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 646. Australia Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 647. Australia Ganirelix Sales, by Route K Units (2025-2030)
  • Table 648. Rest of Asia-Pacific Ganirelix Sales, by Application K Units (2025-2030)
  • Table 649. Rest of Asia-Pacific Ganirelix Sales, by Form K Units (2025-2030)
  • Table 650. Rest of Asia-Pacific Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 651. Rest of Asia-Pacific Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 652. Rest of Asia-Pacific Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 653. Rest of Asia-Pacific Ganirelix Sales, by Route K Units (2025-2030)
  • Table 654. Europe Ganirelix Sales, by Country K Units (2025-2030)
  • Table 655. Europe Ganirelix Sales, by Application K Units (2025-2030)
  • Table 656. Europe Ganirelix Sales, by Form K Units (2025-2030)
  • Table 657. Europe Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 658. Europe Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 659. Europe Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 660. Europe Ganirelix Sales, by Route K Units (2025-2030)
  • Table 661. Germany Ganirelix Sales, by Application K Units (2025-2030)
  • Table 662. Germany Ganirelix Sales, by Form K Units (2025-2030)
  • Table 663. Germany Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 664. Germany Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 665. Germany Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 666. Germany Ganirelix Sales, by Route K Units (2025-2030)
  • Table 667. France Ganirelix Sales, by Application K Units (2025-2030)
  • Table 668. France Ganirelix Sales, by Form K Units (2025-2030)
  • Table 669. France Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 670. France Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 671. France Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 672. France Ganirelix Sales, by Route K Units (2025-2030)
  • Table 673. Italy Ganirelix Sales, by Application K Units (2025-2030)
  • Table 674. Italy Ganirelix Sales, by Form K Units (2025-2030)
  • Table 675. Italy Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 676. Italy Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 677. Italy Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 678. Italy Ganirelix Sales, by Route K Units (2025-2030)
  • Table 679. United Kingdom Ganirelix Sales, by Application K Units (2025-2030)
  • Table 680. United Kingdom Ganirelix Sales, by Form K Units (2025-2030)
  • Table 681. United Kingdom Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 682. United Kingdom Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 683. United Kingdom Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 684. United Kingdom Ganirelix Sales, by Route K Units (2025-2030)
  • Table 685. Netherlands Ganirelix Sales, by Application K Units (2025-2030)
  • Table 686. Netherlands Ganirelix Sales, by Form K Units (2025-2030)
  • Table 687. Netherlands Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 688. Netherlands Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 689. Netherlands Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 690. Netherlands Ganirelix Sales, by Route K Units (2025-2030)
  • Table 691. Rest of Europe Ganirelix Sales, by Application K Units (2025-2030)
  • Table 692. Rest of Europe Ganirelix Sales, by Form K Units (2025-2030)
  • Table 693. Rest of Europe Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 694. Rest of Europe Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 695. Rest of Europe Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 696. Rest of Europe Ganirelix Sales, by Route K Units (2025-2030)
  • Table 697. MEA Ganirelix Sales, by Country K Units (2025-2030)
  • Table 698. MEA Ganirelix Sales, by Application K Units (2025-2030)
  • Table 699. MEA Ganirelix Sales, by Form K Units (2025-2030)
  • Table 700. MEA Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 701. MEA Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 702. MEA Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 703. MEA Ganirelix Sales, by Route K Units (2025-2030)
  • Table 704. Middle East Ganirelix Sales, by Application K Units (2025-2030)
  • Table 705. Middle East Ganirelix Sales, by Form K Units (2025-2030)
  • Table 706. Middle East Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 707. Middle East Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 708. Middle East Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 709. Middle East Ganirelix Sales, by Route K Units (2025-2030)
  • Table 710. Africa Ganirelix Sales, by Application K Units (2025-2030)
  • Table 711. Africa Ganirelix Sales, by Form K Units (2025-2030)
  • Table 712. Africa Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 713. Africa Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 714. Africa Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 715. Africa Ganirelix Sales, by Route K Units (2025-2030)
  • Table 716. North America Ganirelix Sales, by Country K Units (2025-2030)
  • Table 717. North America Ganirelix Sales, by Application K Units (2025-2030)
  • Table 718. North America Ganirelix Sales, by Form K Units (2025-2030)
  • Table 719. North America Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 720. North America Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 721. North America Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 722. North America Ganirelix Sales, by Route K Units (2025-2030)
  • Table 723. United States Ganirelix Sales, by Application K Units (2025-2030)
  • Table 724. United States Ganirelix Sales, by Form K Units (2025-2030)
  • Table 725. United States Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 726. United States Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 727. United States Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 728. United States Ganirelix Sales, by Route K Units (2025-2030)
  • Table 729. Canada Ganirelix Sales, by Application K Units (2025-2030)
  • Table 730. Canada Ganirelix Sales, by Form K Units (2025-2030)
  • Table 731. Canada Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 732. Canada Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 733. Canada Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 734. Canada Ganirelix Sales, by Route K Units (2025-2030)
  • Table 735. Mexico Ganirelix Sales, by Application K Units (2025-2030)
  • Table 736. Mexico Ganirelix Sales, by Form K Units (2025-2030)
  • Table 737. Mexico Ganirelix Sales, by Packaging K Units (2025-2030)
  • Table 738. Mexico Ganirelix Sales, by Clearance K Units (2025-2030)
  • Table 739. Mexico Ganirelix Sales, by Strength K Units (2025-2030)
  • Table 740. Mexico Ganirelix Sales, by Route K Units (2025-2030)
  • Table 741. Research Programs/Design for This Report
  • Table 742. Key Data Information from Secondary Sources
  • Table 743. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Ganirelix: by Application USD Million (2018-2023)
  • Figure 5. Global Ganirelix: by Form USD Million (2018-2023)
  • Figure 6. Global Ganirelix: by Packaging USD Million (2018-2023)
  • Figure 7. Global Ganirelix: by Clearance USD Million (2018-2023)
  • Figure 8. Global Ganirelix: by Strength USD Million (2018-2023)
  • Figure 9. Global Ganirelix: by Route USD Million (2018-2023)
  • Figure 10. South America Ganirelix Share (%), by Country
  • Figure 11. Asia Pacific Ganirelix Share (%), by Country
  • Figure 12. Europe Ganirelix Share (%), by Country
  • Figure 13. MEA Ganirelix Share (%), by Country
  • Figure 14. North America Ganirelix Share (%), by Country
  • Figure 15. Global Ganirelix: by Application K Units (2018-2023)
  • Figure 16. Global Ganirelix: by Form K Units (2018-2023)
  • Figure 17. Global Ganirelix: by Packaging K Units (2018-2023)
  • Figure 18. Global Ganirelix: by Clearance K Units (2018-2023)
  • Figure 19. Global Ganirelix: by Strength K Units (2018-2023)
  • Figure 20. Global Ganirelix: by Route K Units (2018-2023)
  • Figure 21. South America Ganirelix Share (%), by Country
  • Figure 22. Asia Pacific Ganirelix Share (%), by Country
  • Figure 23. Europe Ganirelix Share (%), by Country
  • Figure 24. MEA Ganirelix Share (%), by Country
  • Figure 25. North America Ganirelix Share (%), by Country
  • Figure 26. Global Ganirelix share by Players 2023 (%)
  • Figure 27. Global Ganirelix share by Players (Top 3) 2023(%)
  • Figure 28. Global Ganirelix share by Players (Top 5) 2023(%)
  • Figure 29. BCG Matrix for key Companies
  • Figure 30. Organon USA Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Organon USA Inc. (United States) Revenue: by Geography 2023
  • Figure 32. Ferring Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Ferring Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 34. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 35. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2023
  • Figure 36. Chemenu Inc. (China) Revenue, Net Income and Gross profit
  • Figure 37. Chemenu Inc. (China) Revenue: by Geography 2023
  • Figure 38. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 40. BLD Pharm (China) Revenue, Net Income and Gross profit
  • Figure 41. BLD Pharm (China) Revenue: by Geography 2023
  • Figure 42. LGM Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 43. LGM Pharma (United States) Revenue: by Geography 2023
  • Figure 44. Angle Bio Pharma (India) Revenue, Net Income and Gross profit
  • Figure 45. Angle Bio Pharma (India) Revenue: by Geography 2023
  • Figure 46. Global Ganirelix: by Application USD Million (2025-2030)
  • Figure 47. Global Ganirelix: by Form USD Million (2025-2030)
  • Figure 48. Global Ganirelix: by Packaging USD Million (2025-2030)
  • Figure 49. Global Ganirelix: by Clearance USD Million (2025-2030)
  • Figure 50. Global Ganirelix: by Strength USD Million (2025-2030)
  • Figure 51. Global Ganirelix: by Route USD Million (2025-2030)
  • Figure 52. South America Ganirelix Share (%), by Country
  • Figure 53. Asia Pacific Ganirelix Share (%), by Country
  • Figure 54. Europe Ganirelix Share (%), by Country
  • Figure 55. MEA Ganirelix Share (%), by Country
  • Figure 56. North America Ganirelix Share (%), by Country
  • Figure 57. Global Ganirelix: by Application K Units (2025-2030)
  • Figure 58. Global Ganirelix: by Form K Units (2025-2030)
  • Figure 59. Global Ganirelix: by Packaging K Units (2025-2030)
  • Figure 60. Global Ganirelix: by Clearance K Units (2025-2030)
  • Figure 61. Global Ganirelix: by Strength K Units (2025-2030)
  • Figure 62. Global Ganirelix: by Route K Units (2025-2030)
  • Figure 63. South America Ganirelix Share (%), by Country
  • Figure 64. Asia Pacific Ganirelix Share (%), by Country
  • Figure 65. Europe Ganirelix Share (%), by Country
  • Figure 66. MEA Ganirelix Share (%), by Country
  • Figure 67. North America Ganirelix Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Organon USA Inc. (United States)
  • Ferring Pharmaceuticals Inc. (United States)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Chemenu Inc. (China)
  • Merck & Co., Inc. (United States)
  • BLD Pharm (China)
  • LGM Pharma (United States)
  • Angle Bio Pharma (India)
Select User Access Type

Key Highlights of Report


Feb 2024 238 Pages 61 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Ganirelix Market Quantitative research analysis
Global Ganirelix Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Organon USA Inc. (United States), Ferring Pharmaceuticals Inc. (United States), Sun Pharmaceutical Industries Ltd. (India), Chemenu Inc. (China), Merck & Co., Inc. (United States), BLD Pharm (China), LGM Pharma (United States) and Angle Bio Pharma (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Advancements in Infertility Treatment" is seen as one of major influencing trends for Ganirelix Market during projected period 2023-2030.
The Ganirelix market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Ganirelix Market Report?

Have a Query? Click Here

Other Related Reports

Carisoprodol Tablets Comprehensive Study by Type (Carisoprodol 250 mg Tablet, Carisoprodol 350 mg Tablet), End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Ph...
$ 3350
Disclosing Tablets Comprehensive Study by Composition (Erythrosine, Fluorescein, Iodine), Ager group (Children, Adults, Geriatric Population), Distribution Channel (Online, Medical Stores, Pharmacies...
$ 3450
Bromperidol Comprehensive Study by Application (Dementia, Depression, Schizophrenia, Anxiety Disorders, Psychosomatic Disorders, Others), Size (100mg, 200mg, 500mg, Others), Dosage Form (Tablet, Inj...
$ 3350
Mebeverine Comprehensive Study by Type (Tablets, Capsules, Liquid), Application (Abdominal Pain and Cramps, Constipation, Diarrhea, Flatulence), Distribution Channel (Hospital Pharmacies, Retail Phar...
$ 3450
Levobupivacaine Comprehensive Study by Application (Oral Surgery Procedures, Diagnostic And Therapeutic Procedures, Obstetrical Procedures, Others), Patient Type (Adult, Elderly), Contraindication (H...
$ 3750
Apomorphine Hydrochloride Comprehensive Study by Type (Pen Injectors, Infusion Pumps), Application (Parkinson Disease, Erectile Dysfunction) Players and Region - Global Market Outlook to 2026
$ 3500